WinRho®SDF(1.9 ug), IgG1Rh113 (4.0 ug), IgG1Rh178 (1.1 ug), IgG1r9B8 (3.0 ug), IgG3r9B8
Introduction
Autoimmune thrombocytopenic purpura (AITP) is a bleeding disorder where platelets are opsonized by autoantibodies and destroyed by Fc receptor (R)-mediated phagocytosis.
1,2 Treatment options can include corticosteroids or splenectomy, and if these fail to raise platelet counts, more potent compounds may be used. 1, 2 Rh immune globulin (WinRho® SDF) also increases platelet counts in AITP, [3] [4] [5] however, the competition for supplies of WinRho® SDF for it's primary indication, hemolytic disease of the newborn (HDN), has limited its use in AITP. A potential alternative to
WinRho®SDF is the use of MoAnti-D.
The D antigen is a 32 kD erythrocyte (RBC) protein encoded by the RHD gene which has several allelic variants that is able to generate different epitopes allowing the production of many
MoAnti-D. [6] [7] [8] [9] [10] [11] [12] [13] Hundreds of MoAnti-D have been produced for phenotypic studies and many have been characterized for their ability to inhibit physiological processes in models of HDN. [9] [10] [11] [12] [13] With respect to AITP, however, only one study attempted to treat AITP patients with MoAnti-D, but platelet counts were not increased. 14 It was suggested that the failure was due to the monoclonal preparation missing factors present in polyclonal anti-D. 15 Subsequently, few studies attempted to understand why MoAnti-D preparations are not effective in AITP. This study examined the ability of MoAnti-D to inhibit opsonized platelet phagocytosis in vitro and results demonstrate that both epitope specificity and isotype need to be considered for production of a MoAnti-D preparation that mimics the effects of polyclonal WinRho® SDF.
Material and Methods
Antibodies: Serum prepared from a patient with AITP previously screened for high-titred IgG anti- Phagocytosis Assay: Phagocytosis of platelets was performed by a method previously described. Statistical analysis: An unpaired t test for comparison between means was used.
Results and Discussion
When labeled platelets were opsonized with W6/32, a significant increase in THP-1 intracellular fluorescence was observed as previously described ( Figure 1A and B). 17 When nonopsonized RBC were added, there was no effect on W6/32-opsonized or autoantibody-opsonized platelet phagocytosis at any RBC:THP-1 ratio ( Figures 1C and 1D ). RBC opsonized with WinRho® SDF, however, mediated a significant (p<0.0001) Fc-dependent inhibition of both W6/32-and autoantibody-mediated platelet phagocytosis ( Figures 1C and 1D In an attempt to address these issues, we mixed the 6 MoAb expecting that the 3 non-inhibitory antibodies would confer at least some of their lack of inhibition, however, the mixture significantly inhibited platelet phagocytosis as well as WinRho®SDF ( Figure 2D ). This paradoxical finding may be related to studies demonstrating that blending different IgG1 and IgG3 7 isotypes of MoAnti-D can synergistically inhibit erythrophagocytosis in HDN and respiratory burst in monocytes.
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In conclusion, MoAnti-D inhibition of opsonized platelet phagocytosis is dependent on isotype and epitope specificity suggesting that these preparations can be produced to mimic polyclonal anti-D and perhaps be therapeutically effective in AITP. C. D.
